Results from a phase 2b, randomized, multicenter study of GVAX pancreas and CRS-207 compared to chemotherapy in adults with previously-treated metastatic pancreatic adenocarcinoma (ECLIPSE Study).

@inproceedings{Le2017ResultsFA,
  title={Results from a phase 2b, randomized, multicenter study of GVAX pancreas and CRS-207 compared to chemotherapy in adults with previously-treated metastatic pancreatic adenocarcinoma (ECLIPSE Study).},
  author={Dung T Le and Andrew H. Ko and Zev A. Wainberg and Vincent J. Picozzi and Karen Springmyer Johnson and Andrea Wang-Gillam and Paul E Oberstein and Michael A. Morse and Herbert J. Zeh and Colin Weekes and Tony Reid and Aimee Luck Murphy and K. Mcdougall and Chan C. Whiting and Nitya Nair and Amanda Enstrom and Sandy Ferber and Thomas W Dubensky and Dirk G. Brockstedt and Elizabeth M Jaffee},
  year={2017}
}
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD Virginia Mason Medical Center, Seattle, WA University of California San Francisco, San Francisco, CA University of California Los Angeles, Los Angeles, CA University of Chicago Medical Center, Chicago, IL Washington University School of Medicine in St. Louis, St. Louis, MO Columbia University Medical Center, New York, NY Duke University Medical Center, Durham, NC University of Pittsburgh Medical Center, Pittsburgh, PA… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 15 CITATIONS

Pancreatic cancer microenvironment: a current dilemma

  • Clinical and translational medicine
  • 2019
VIEW 2 EXCERPTS
CITES BACKGROUND

Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer

  • International journal of molecular sciences
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 19 REFERENCES

IDO1 in cancer: a Gemini of immune checkpoints

  • Cellular & Molecular Immunology
  • 2018
VIEW 1 EXCERPT

Similar Papers

Loading similar papers…